Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapy resistance

JAK inhibition shows two faces in prostate cancer

Therapeutic resistance in prostate cancer can be driven by lineage plasticity, but the mechanisms behind this are unclear, and therapies to prevent or reverse the process are nonexistent. A new study reveals the JAK/STAT signaling axis as a driver of lineage plasticity with tremendous therapeutic potential.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: JAK/STAT signaling and lineage plasticity.

References

  1. Bluemn, E. G. et al. Cancer Cell 32, 474–489 e6 (2017).

    CAS  Article  Google Scholar 

  2. Beltran, H. et al. Nat. Med. 22, 298–305 (2016).

    CAS  Article  Google Scholar 

  3. Beltran, H. et al. J. Clin. Invest. 130, 1653–1668 (2020).

    Article  Google Scholar 

  4. Berger, A. et al. 129, 3924-3940 (2019).

  5. Augello, M. A. et al. Cancer Cell 35, 603–617 e8 (2019).

    CAS  Article  Google Scholar 

  6. Zhang, Z. et al. Cancer Cell 37, 584–598 e11 (2020).

    CAS  Article  Google Scholar 

  7. Ku, S. Y. et al. Science 355, 78–83 (2017).

    CAS  Article  Google Scholar 

  8. Brady, N. J. et al. Nat. Commun. 12, 3372 (2021).

    CAS  Article  Google Scholar 

  9. Lee, J. K. et al. Cancer Cell 29, 536–547 (2016).

    CAS  Article  Google Scholar 

  10. Dardenne, E. et al. Cancer Cell 30, 563–577 (2016).

    CAS  Article  Google Scholar 

  11. Bishop, J. L. et al. Cancer Discov. 7, 54–71 (2017).

    CAS  Article  Google Scholar 

  12. Mu, P. et al. Science 355, 84–88 (2017).

    CAS  Article  Google Scholar 

  13. Deng, S. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00431-9 (2022).

    Article  PubMed  Google Scholar 

  14. Tang, F. et al. Science 376, eabe1505 (2022).

    CAS  Article  Google Scholar 

  15. Irey, E. A. et al. Proc. Natl Acad. Sci. USA 116, 12442–12451 (2019).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christopher E. Barbieri.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brady, N.J., Barbieri, C.E. JAK inhibition shows two faces in prostate cancer. Nat Cancer 3, 1021–1023 (2022). https://doi.org/10.1038/s43018-022-00437-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00437-3

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer